Sign in

    Danya Ben-Hail • JonesTrading Institutional Services

    Danya Ben-Hail is a Research Associate in Equity Research at JonesTrading Institutional Services, specializing in biotechnology company analysis within the healthcare sector. She currently covers a range of biotechnology firms, leveraging her scientific background to deliver in-depth evaluations, though specific coverage companies and performance metrics are not publicly disclosed. Ben-Hail began her analytical career after earning a doctorate from Ben-Gurion University of the Negev and previously served as Associate Consultant at Cello Health BioConsulting, focusing on oncology, autoimmune, and rare diseases. Her credentials include advanced scientific training, but registrations with regulatory authorities or securities licenses have not been publicly confirmed.

    Danya Ben-Hail's questions to Curis Inc (CRIS) leadership

    Danya Ben-Hail's questions to Curis Inc (CRIS) leadership • Q2 2025

    Question

    Danya Ben-Hail of JonesTrading asked about expectations for the next PCNSL data update, plans for additional clinical sites, and the targeted line of therapy for the new CLL program.

    Answer

    CEO James Dentzer noted ASH is the next likely conference for a PCNSL update but gave no specific guidance, confirming enrollment is on track without needing new sites. CMO Ahmed Hamdy explained the CLL study will enroll patients on a BTK inhibitor who have not achieved a complete remission, regardless of the line of therapy.

    Ask Fintool Equity Research AI

    Danya Ben-Hail's questions to Curis Inc (CRIS) leadership • Q1 2025

    Question

    Danya Ben-Hail from Jones Research, on behalf of Soumit Roy, asked for details on which genetic mutations might affect patient responses to emavusertib and requested an update on the development strategy for the drug in relapsed/refractory AML.

    Answer

    President and CEO James Dentzer explained that it is too early to comment on specific mutations, emphasizing that the drug's dual-pathway mechanism of action is the primary driver of efficacy. Chief Development Officer Jonathan Zung stated that future plans for AML development, including for the relapsed/refractory setting, will be outlined after the current triplet safety study is complete.

    Ask Fintool Equity Research AI